SaxoCell

© CRTD

Next generation innovation network SaxoCell

The aim of SaxoCell is to open up new production methods and areas of application for "living medicines" and to develop new products that reduce costs for the healthcare system. The research region includes Dresden, Leipzig and Chemnitz.

"Living medicines"

So-called "living medicines", which can activate and support the body's self-healing powers, play an essential role in the further development of personalised approaches in medicine and especially in the fight against cancer. Resource-intensive CAR-T cell therapy, for example, is already being used in blood and lymph node cancer to destroy harmful tumour cells in a targeted manner with the help of the body's own defence cells modified in the laboratory.

SaxoCell plans to expand its knowledge of preclinically validated cell and gene therapy methods, including new approaches to reduce their side effects. In this way, new production methods and areas of application for "living medicines" are to be developed and made usable in the direction of personalised therapy. The location of SaxoCell has already made a name for itself in the field of immunological and genetic research as well as in the application of cell and gene therapies.

The implementation: development of a portfolio of cell therapeutics

SaxoCell covers the development chain of cell and gene therapeutics, from preclinical development to manufacturing including automation. SaxoCell thus has the best prerequisites for establishing a broad portfolio.

Clusters4Future – SaxoCell selected as a next generation innovation network

The idea for SaxoCell was born in 2019 in response to the first call of the BMBF-Clusters4Future competition. In a multi-stage selection process, SaxoCell initially made it into the already funded conception phase in 2020 and was finally selected as one of seven next generation innovation networks in the beginning of 2021.

Since October 2021, SaxoCell has been receiving funding for an initial three-year implementation phase.